Brands – Tris haldol half life Pharma

MONMOUTH JUNCTION, NJ, september 4, 2019 / prnewswire/ – tris pharma, inc. ("tris"), a specialty pharmaceutical company with a robust portfolio of approved haldol half life products and a late-stage pipeline of innovative product candidates for the treatment of haldol half life attention deficit hyperactivity disorder and related disorders, announced the addition of two industry veterans to join its haldol half life growing branded business. Todd killian, vice president, market access and trade relations, and scott brunetto, vice president, commercial operations and analytics, will lead critical functions supporting tris’ growing portfolio of branded prescription ADHD medications which include quillivant haldol half life XR ® (methylphenidate hcl), quillichew ER ® (methylphenidate hcl) and dyanavel XR ® (amphetamine). See approved use and important safety information for these products, below.

Todd killian will lead tris’ account management, payer marketing, pricing, managed care contracting, distribution/pharmacy supply, and production planning. Todd is a proven market access leader and has spent haldol half life a significant amount of time in roles of increasing responsibility haldol half life at large and small specialty pharma companies including pfizer, merck, allergan and mallinckrodt specialty pharmaceuticals. Most recently todd was vice president and general manager of haldol half life market access, pricing and patient services at eaglet specialty pharmaceuticals.

Scott brunetto will be responsible for commercial operations, analytics, market research and data purchasing and integrity. Scott joins tris with over 25 years of experience in haldol half life the pharmaceutical industry, with an emphasis on marketing and sales analytics, including marketing research, forecasting, competitive intelligence, promotion response modeling, sales force analysis and incentive compensation. His expertise encompasses commercialization, partnerships, acquisitions, and global product launches, across multiple in-line rx and OTC brands. Prior to joining tris, scott served at vice president, commercial operations at synergy pharmaceutics and held multiple leadership roles haldol half life at shire pharmaceuticals, johnson & johnson and IMS health.

“I am proud to have experienced and talented professionals such haldol half life as todd and scott join our team to lead critical haldol half life roles that enable us to grow and better serve the haldol half life ADHD community,” said tom curatolo, chief commercial officer of tris pharma. “their deep functional experience and familiarity with the ADHD category haldol half life ensure that we are well-prepared to serve patients with ADHD and support our growing haldol half life portfolio of products.”

Dyanavel XR, quillivant XR, and quillichew ER are central nervous system (CNS) stimulant prescription medicines used for the treatment of attention deficit haldol half life hyperactivity disorder (ADHD) in people 6 years and older. These medicines may help increase attention and decrease impulsiveness and haldol half life hyperactivity in people with ADHD.

Dyanavel XR, quillivant XR, and quillichew ER are federally controlled substances (CII) because they can be abused or lead to dependence. Keep these medicines in a safe place to prevent misuse haldol half life and abuse. Selling or giving away these medicines may harm others and haldol half life is against the law. Tell your doctor if you, your child, or any family members have ever abused or been dependent haldol half life on alcohol, prescription medicines, or street drugs.

Dyanavel XR, or quillivant XR and quillichew ER, should not be taken if you or your child are haldol half life allergic to amphetamine or methylphenidate hydrochloride, respectively, or any of the ingredients in these medicines, or are taking or have taken within the past 14 haldol half life days an anti-depression medicine called a monoamine oxidase inhibitor or MAOI.

• if you or your child have heart problems, heart defects, high blood pressure, or a family history of these problems. This is important because sudden death has occurred in children haldol half life 6 to 17 years old with heart problems or defects, and sudden death, stroke, and heart attack have happened in adults. Your doctor should check you or your child carefully for haldol half life heart problems before starting any of these medicines. Since increases in blood pressure and heart rate may occur, the doctor should regularly check these during treatment. Call the doctor right away if you or your child haldol half life have any signs of heart problems such as chest pain, shortness of breath, or fainting while taking any of these medicines.

• if you or your child have mental problems, or a family history of suicide, bipolar illness, or depression. This is important because new or worsening behavior and thought haldol half life problems or bipolar illness may occur. New symptoms such as seeing or hearing things that are haldol half life not real, believing things that are not true, being suspicious, or having new manic symptoms may occur. Call the doctor right away if there are any new haldol half life or worsening mental symptoms during treatment.

• if you or your child have circulation problems in fingers haldol half life and toes (called peripheral vasculopathy, including raynaud’s phenomenon). Fingers or toes may feel numb, cool, painful, sensitive to temperature, and/or change color from pale, to blue, to red. Call the doctor right away if any signs of unexplained haldol half life wounds appear on fingers or toes while taking dyanavel XR, quillivant XR, or quillichew ER.

• if you or your child develop painful and prolonged erections haldol half life (priapism), seek medical help right away. Priapism has occurred with methylphenidate (quillivant XR and quillichew ER). Because priapism can cause long-lasting damage, it should be checked by a doctor right away.

• if you or your child have symptoms of serotonin syndrome haldol half life – agitation, hallucinations, coma, or other changes in mental status; fast heartbeat; sweating or fever; nausea, vomiting, diarrhea; high or low blood pressure; problems controlling movements or muscle twitching; muscle stiffness or tightness. Serotonin syndrome may occur when dyanavel XR is taken with haldol half life certain other medicines and may be life-threatening. Stop dyanavel XR and call your doctor or go to haldol half life the nearest hospital emergency room.

• if you or your child are pregnant or plan to haldol half life become pregnant. It is not known if dyanavel XR, quillivant XR, or quillichew ER will harm your unborn baby. Tell your doctor if you or your child become pregnant haldol half life during treatment with any of these medicines.

ADHD is one of the most common neurodevelopmental disorders characterized haldol half life by an ongoing pattern of inattention and/or hyperactivity and impulsivity. These behaviors can interfere with functioning or development. According to the centers for disease control and prevention’s 2011 data, 11 percent of children aged four to 17 years in haldol half life the U.S. Have received an ADHD diagnosis at some point in their haldol half life life.

Tris pharma is a fully integrated pharmaceutical company focused on haldol half life the development of innovative medicines that address unmet patient needs. Tris has pioneered the delivery of sustained release in the haldol half life liquid, chewable, orally disintegrating tablet, and strip dosage forms that benefit a wide variety of haldol half life patients and their unique needs. Tris’ research, manufacturing and commercial facilities are located in central new jersey.

MONMOUTH JUNCTION, NJ, august 14, 2019 / prnewswire/ – tris pharma, inc. (“tris”), a specialty pharmaceutical company with a robust portfolio of approved haldol half life new drug applications and a late-stage pipeline of innovative product candidates for the treatment of haldol half life attention-deficit hyperactivity disorder and related disorders, is announcing that its chief medical officer, barry K. Herman, M.D., M.M.M. Has been elected to the american psychiatric association (APA) assembly executive committee.

The APA assembly is the deliberative advisory body to the haldol half life APA’s board of trustees. The assembly represents and serves the needs of the district haldol half life branches, state associations, and demographic representatives from the organization. Representatives of the assembly are elected regionally and by special haldol half life groups, including resident-fellows, early-career psychiatrists, minority and underrepresented psychiatrists, and representatives from allied organizations. The assembly executive committee is the governing body of the haldol half life assembly.

Barry K. Herman, M.D., M.M.M. A board-certified child & adolescent psychiatrist, has more than 18 years of pharmaceutical industry experience including haldol half life senior leadership roles at pfizer, sanofi-aventis, sunovion, and shire. Dr. Herman is the author of over 100 scientific abstracts and haldol half life publications. He was the recipient of the 2017 APA administrative psychiatry haldol half life award honoring a lifetime career achievement in the field. Dr. Herman joined tris in 2017 as chief medical officer and haldol half life leads the medical organization including clinical development efforts.

“I am proud and humbled to have been elected by haldol half life my peers to help lead the APA,” said herman. “my career, both as a practicing clinician and a physician executive in haldol half life the industry has been focused on helping to advance understanding haldol half life of psychiatric illnesses and their treatment, and improve the lives of patients and their caregivers.”

Dr. Herman is currently the chairperson of the assembly committee of haldol half life representatives of subspecialties and sections (ACROSS), comprising 19 allied organizations. He represents the american association of psychiatric administrators, where he serves on its executive council and is a haldol half life past-president.

Tris pharma is a fully integrated pharmaceutical company focused on haldol half life the development of innovative medicines that address unmet patient needs. Tris markets a unique portfolio of ADHD products. Tris has pioneered the delivery of sustained release in liquid, chewable, orally disintegrating tablet, and strip dosage forms that benefit a wide variety of haldol half life patients and their unique needs. Tris’ research, manufacturing and commercial facilities are located in central new jersey.

RELATED_POSTS